Federal Circuit Affirms District Court’s Claim Construction Of “Branched Alkyl” In mRNA Vaccine Patent Dispute

Start
On June 4, 2025, the United States Court of Appeals for the Federal Circuit (Judges Taranto, Chen, and Hughes) affirmed the District of Delaware’s claim construction in a patent infringement dispute involving lipid components used in Moderna’s (Moderna, Inc., ModernaTX, Inc., and Moderna US, Inc.) mRNA-based COVID-19 vaccine. The case centered on the interpretation of the term “branched alkyl” as recited in U.S. Patent Nos. 11,246,933 and 11,382,979, both owned by Alnylam Pharmaceuticals, Inc….
By: A&O Shearman
Previous Story

North Dakota Passes New Data Security Law for “Financial Corporations”

Next Story

Northern District Of California Narrows Claims In Securities Class Action Against Medical Devices Company